| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
DMT-dT Phosphoramidite does not have a specific biological target itself but serves as a chemical building block for DNA synthesis. When incorporated into oligonucleotides, the resulting DNA sequences can target various biological molecules for applications such as gene editing, diagnostics, and molecular biology research. The DMT group provides 5'-hydroxyl protection for controlled chain elongation during solid-phase synthesis. The compound is a thymidine analog used to incorporate thymine residues into synthetic DNA sequences.
|
|---|---|
| ln Vitro |
The in vitro activity of DMT-dT Phosphoramidite is assessed by its utility as a building block in DNA synthesis. The efficiency of incorporation into growing oligonucleotide chains during solid-phase synthesis is evaluated by monitoring coupling efficiency. The purity of the compound and its suitability for automated DNA synthesis are assessed by HPLC analysis. The resulting DNA oligonucleotides are evaluated for their ability to hybridize to complementary sequences using thermal melting (Tm) analysis.
|
| ln Vivo |
In vivo studies for DMT-dT Phosphoramidite are typically conducted on the DNA oligonucleotides synthesized using this building block rather than the phosphoramidite itself. These oligonucleotides are evaluated in animal models for their pharmacokinetic properties, biodistribution, and therapeutic efficacy in applications such as gene editing or nucleic acid-based therapeutics. The DMT and cyanoethyl protecting groups are removed during oligonucleotide synthesis and deprotection.
|
| Enzyme Assay |
For oligonucleotide synthesis, DMT-dT Phosphoramidite is dissolved in anhydrous acetonitrile and coupled to the growing oligonucleotide chain using standard solid-phase synthesis protocols. Coupling efficiency is monitored by trityl cation release measurements at each synthesis cycle. After synthesis, the oligonucleotide is cleaved from the solid support and deprotected using concentrated ammonia solution (8 hours at 55°C or 24 hours at room temperature). The final oligonucleotide is purified by HPLC or PAGE and characterized by mass spectrometry.
|
| Cell Assay |
For cellular studies, cultured cells are treated with DNA oligonucleotides synthesized using DMT-dT Phosphoramidite as a building block. Cells are incubated with oligonucleotides for 24-72 hours, and cellular uptake is assessed by fluorescence microscopy or flow cytometry using fluorescently labeled oligonucleotides. For gene editing applications, the efficiency of gene modification is evaluated using appropriate assays. Cytotoxicity is assessed using MTT or CellTiter-Glo assays.
|
| Animal Protocol |
For in vivo evaluation of DNA oligonucleotides, mice or rats are administered the oligonucleotides via various routes. Pharmacokinetic parameters including half-life, clearance, and tissue distribution are determined by measuring oligonucleotide concentrations in plasma and tissues using hybridization-based assays or LC-MS. For therapeutic applications, efficacy is evaluated in appropriate disease models, with disease biomarkers or survival monitored over time.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of DMT-dT Phosphoramidite are characterized for the DNA oligonucleotides incorporating this building block rather than the phosphoramidite itself. The compound is typically handled as a solid and stored at -20°C under inert gas to maintain stability. It has a molecular weight of 744.81 and purity specifications range from >98% (HPLC) to ≥99.5% (HPLC) for higher-grade material. Detailed PK parameters depend on the specific oligonucleotide sequence and backbone chemistry.
|
| Toxicity/Toxicokinetics |
The toxicity profile of DMT-dT Phosphoramidite is not explicitly detailed in the provided sources. As a chemical reagent, standard laboratory safety precautions should be followed when handling it. It is intended for research use only and is not for human therapeutic applications. The compound's safety would be evaluated in the context of the final oligonucleotide product rather than the phosphoramidite itself.
|
| References | |
| Additional Infomation |
DMT-dT Phosphoramidite is a foundational nucleoside building block for solid-phase DNA synthesis. With a molecular formula of C40H49N4O8P and a purity of ≥99% (31P-NMR), it contains a DMT protecting group and a cyanoethyl phosphoramidite moiety. It is used to incorporate thymine residues into synthetic DNA for applications like gene editing and diagnostics. This research compound is for laboratory use only and is not for human therapeutic applications.
|
| Molecular Formula |
C40H49N4O8P
|
|---|---|
| Molecular Weight |
744.81
|
| Exact Mass |
744.328
|
| Elemental Analysis |
C, 64.50; H, 6.63; N, 7.52; O, 17.18; P, 4.16
|
| CAS # |
98796-51-1
|
| Related CAS # |
DMT-dT Phosphoramidite-13C10,15N2;2483830-17-5;DMT-dT Phosphoramidite-15N2
|
| PubChem CID |
9940288
|
| Appearance |
White to off-white solid powder
|
| LogP |
8.09
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
53
|
| Complexity |
1240
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COC(C3=CC=CC=C3)(C4=CC=C(C=C4)OC)C5=CC=C(C=C5)OC)OP(N(C(C)C)C(C)C)OCCC#N
|
| InChi Key |
UNOTXUFIWPRZJX-CEXSRUIHSA-N
|
| InChi Code |
InChI=1S/C40H49N4O8P/c1-27(2)44(28(3)4)53(50-23-11-22-41)52-35-24-37(43-25-29(5)38(45)42-39(43)46)51-36(35)26-49-40(30-12-9-8-10-13-30,31-14-18-33(47-6)19-15-31)32-16-20-34(48-7)21-17-32/h8-10,12-21,25,27-28,35-37H,11,23-24,26H2,1-7H3,(H,42,45,46)/t35-,36+,37+,53?/m0/s1
|
| Chemical Name |
3-[[(2R,3S,5R)-2-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-[di(propan-2-yl)amino]phosphanyl]oxypropanenitrile
|
| Synonyms |
DMT-dT Phosphoramidite; 5'-O-DMT-Thymidine-CE Phosphoramidite
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~335.7 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (2.79 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (2.79 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3426 mL | 6.7131 mL | 13.4262 mL | |
| 5 mM | 0.2685 mL | 1.3426 mL | 2.6852 mL | |
| 10 mM | 0.1343 mL | 0.6713 mL | 1.3426 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
